En först-på-människa-studie av BG-C0979 hos vuxna med avancerade solida tumörer
En multicenter, öppen, fas 1a/b, första-in-människa-studie för att undersöka säkerheten, tolerabiliteten, farmakokinetiken och preliminär antitumörverkan av BG-C0979 hos patienter med utvalda avancerade solida tumörer
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Study Director
- Telefonnummer: 8778285568
- E-post: clinicaltrials@beonemed.com
Studieorter
-
-
New South Wales
-
Frenchs Forest, New South Wales, Australien, NSW 2086
- Rekrytering
- Northern Beaches Hospital
-
Liverpool, New South Wales, Australien, NSW 2170
- Rekrytering
- Liverpool Hospital
-
-
Queensland
-
South Brisbane, Queensland, Australien, QLD 4101
- Rekrytering
- Icon Cancer Centre South Brisbane
-
-
Victoria
-
Malvern, Victoria, Australien, VIC 3144
- Rekrytering
- Cabrini Hospital Malvern
-
-
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215-5418
- Rekrytering
- Dana Farber Cancer Institute
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63110-1010
- Rekrytering
- Washington University School of Medicine
-
-
New Jersey
-
Hackensack, New Jersey, Förenta staterna, 07601
- Rekrytering
- John Theurer Cancer Center Hackensack University Medical Center
-
-
Texas
-
San Antonio, Texas, Förenta staterna, 78229
- Rekrytering
- Next Oncology San Antonio
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100021
- Rekrytering
- Cancer Hospital Chinese Academy of Medical Sciences
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Kina, 400037
- Rekrytering
- Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350028
- Rekrytering
- Mengchao Hepatobiliary Hospital of Fujian Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510245
- Rekrytering
- Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
-
-
Hubei
-
Yichang, Hubei, Kina, 443003
- Rekrytering
- Yichang Central Peoples Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 201321
- Rekrytering
- Fudan University Shanghai Cancer Centerpudong
-
-
-
-
-
Barcelona, Spanien, 08036
- Rekrytering
- Hospital Clinic de Barcelona
-
Barcelona, Spanien, 08035
- Rekrytering
- Hospital Universitario Vall Dhebron
-
Madrid, Spanien, 28040
- Rekrytering
- Hospital Universitario Fundacion Jimenez Diaz
-
Madrid, Spanien, 28223
- Rekrytering
- Next Oncology Madrid
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Phase 1a (Monotherapy Dose Escalation and Safety Expansion): Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have previously received standard systemic therapy or for whom treatment is not available or not tolerated, or determined not appropriate based on investigator's judgment.
- Phase 1b Part A (Monotherapy Dose Optimization and Expansion): Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have previously received standard systemic therapy or for whom treatment is not available or not tolerated, or determined not appropriate based on investigator's judgment.
- Phase 1b Part B (Combination Therapy Expansion): Participants with histologically or cytologically confirmed metastatic or unresectable advanced solid tumors who have not received any prior systemic treatment for advanced or metastatic disease.
- Participants must have ≥ 1 measurable lesion as assessed by RECIST v1.1.
- Participants must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Participants must have adequate organ function.
Exclusion Criteria:
- Prior treatment with any ADAM9 (a disintegrin and metalloproteinase domain 9)-targeted antibody-drug conjugates (ADCs) or ADCs containing TOPO1 (DNA topoisomerase 1) inhibitor as payload.
- Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Phase 1a: Monotherapy Dose Escalation
Participants will receive increasing doses of BG-C0979 as monotherapy. |
Administered by intravenous infusion. |
|
Experimentell: Phase 1a: Monotherapy Safety Expansion
Participants will receive BG-C0979 as monotherapy. Selected dose levels that have been determined to be safe in Phase 1a dose escalation will be further evaluated in safety expansion. |
Administered by intravenous infusion. |
|
Experimentell: Phase 1b, Part A: Monotherapy Dose Optimization and Dose Expansion
Participants will receive BG-C0979 as monotherapy in a dose optimization and dose expansion phase at different dose levels of recommended doses for expansion (RDFEs) identified in Phase 1a. |
Administered by intravenous infusion. |
|
Experimentell: Phase 1b, Part B: Combination Therapy Expansion
Participants will receive BG-C0979 in combination with tislelizumab in select tumor types. |
Administered by intravenous infusion. Administered by intravenous infusion.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Phase 1a: Number of Participants Experiencing Adverse Events (AEs)
Tidsram: Up to approximately 24 months
|
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including dose limiting toxicities (DLTs), AEs meeting protocol-defined adverse event of clinical interest (AECI) criteria, laboratory values, and electrocardiogram results. |
Up to approximately 24 months
|
|
Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-C0979 Monotherapy
Tidsram: Up to approximately 10 months
|
MTD or MAD, defined as the highest dose for which the estimated toxicity rate is closest to the target toxicity rate of 28%, or the highest dose administered, respectively. |
Up to approximately 10 months
|
|
Phase 1a: Recommended Dose(s) for Expansion (RDFE[s])
Tidsram: Up to approximately 10 months
|
The potential RDFE(s) of BG-C0979 will be determined based on the totality of data including the MTD or MAD, long-term tolerability, pharmacokinetics (PK), preliminary antitumor activity, and any other relevant data, as available. |
Up to approximately 10 months
|
|
Phase 1b: Recommended Phase 2 Dose (RP2D)
Tidsram: Up to approximately 24 months
|
RP2D of BG-C0979 alone and in combination with tislelizumab will be determined based on safety, PK, preliminary antitumor activity, and other relevant data, as available. |
Up to approximately 24 months
|
|
Phase 1b: Overall Response Rate (ORR)
Tidsram: Up to approximately 24 months
|
ORR as determined from tumor assessment by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. For castration-resistant prostate cancer (CRPC), ORR will be assessed by RECIST v1.1 criteria for soft tissue and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria for bone lesions. ORR is defined as the percentage of participants with best overall response of a complete response (CR) or partial response (PR). |
Up to approximately 24 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Fas 1a: Plasmakoncentration av BG-C0979
Tidsram: Upp till cirka 3 månader
|
Upp till cirka 3 månader
|
|
|
Fas 1a: Ytan under koncentration-tidskurvan (AUC) för BG-C0979
Tidsram: Upp till cirka 3 månader
|
Upp till cirka 3 månader
|
|
|
Fas 1a: Maximal observerad koncentration (Cmax) av BG-C0979
Tidsram: Upp till ungefär 3 månader
|
Upp till ungefär 3 månader
|
|
|
Fas 1a: Tid till maximal koncentration (Tmax) för BG-C0979
Tidsram: Upp till ungefär 3 månader
|
Upp till ungefär 3 månader
|
|
|
Fas 1b: Plasmanivåer av BG-C0979, ensamt och i kombination med Tislelizumab
Tidsram: Upp till cirka 3 månader
|
Upp till cirka 3 månader
|
|
|
Phase 1a: ORR
Tidsram: Up to approximately 24 months
|
ORR as determined from tumor assessment by the investigator using RECIST v1.1. For CRPC, ORR will be assessed by RECIST v1.1 criteria for soft tissue and PCWG3 criteria for bone lesions. ORR is defined as the percentage of participants with best overall response of a complete response (CR) or partial response (PR). |
Up to approximately 24 months
|
|
Phase 1a and 1b: Duration of Response (DOR)
Tidsram: Up to approximately 24 months
|
DOR as determined from tumor assessment by the investigator using RECIST v1.1. For CRPC, DOR will be assessed by RECIST v1.1 criteria for soft tissue and PCWG3 criteria for bone lesions. DOR is defined as the time from the first determination of an objective response until the first documentation of disease progression or death due to any cause, whichever occurs first. |
Up to approximately 24 months
|
|
Phase 1a and 1b: Disease Control Rate (DCR)
Tidsram: Up to approximately 24 months
|
DCR as determined from tumor assessment by the investigator using RECIST v1.1. For CRPC, DCR will be assessed by RECIST v1.1 criteria for soft tissue and PCWG3 criteria for bone lesions. DCR is defined as the percentage of participants with best overall response of a CR, PR, or stable disease. |
Up to approximately 24 months
|
|
Phase 1b: Number of Participants Experiencing Adverse Events (AEs)
Tidsram: Up to approximately 24 months
|
Number of participants with TEAEs and SAEs, including AECIs, laboratory values, and electrocardiogram results. |
Up to approximately 24 months
|
|
Phase 1b: Progression-Free Survival
Tidsram: Up to approximately 24 months
|
PFS is defined as the time from the date of the first administration of study drug(s) to the date of the first documentation of disease progression or death due to any cause, whichever occurs first. |
Up to approximately 24 months
|
|
Phase 1b: Radiographic Progression-Free Survival (rPFS) for Participants with CRPC
Tidsram: Up to approximately 24 months
|
rPFS is defined as the time from the date of the first administration of study drug(s) to the date of the first objective evidence of radiographic disease progression or death due to any cause, whichever occurs first. |
Up to approximately 24 months
|
|
Prostate-Specific Antigen (PSA) Response for Participants with CRPC
Tidsram: Up to approximately 24 months
|
PSA response is defined as a ≥50% decrease in PSA level from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later. |
Up to approximately 24 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Study Director, BeOne Medicines
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- BG-C0979-101
- 2025-524857-15-00 (Ctis)
- CTR20261327 (Annan identifierare: ChinaDrugTrials)
- 2025 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Tidsram för IPD-delning
See plan description
Kriterier för IPD Sharing Access
See plan description
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .